COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB VERSUS ADALIMUMAB, INFLIXIMAB AND VEDOLIZUMAB FOR THE TREATMENT OF PATIENTS WITH MODERATELY TO SEVERE ACTIVE CROHN'S DISEASE FOR TURKEY

Arhan, M.Tezel, H. A.Toruner, M.Bilaloglu, B.Koral, S.Ozer, E.2024-06-122024-06-1220181098-30151524-4733https://doi.org/10.1016/j.jval.2018.09.863https://hdl.handle.net/20.500.14551/25649[Abstract Not Available]en10.1016/j.jval.2018.09.863info:eu-repo/semantics/openAccess[No Keywords]COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB VERSUS ADALIMUMAB, INFLIXIMAB AND VEDOLIZUMAB FOR THE TREATMENT OF PATIENTS WITH MODERATELY TO SEVERE ACTIVE CROHN'S DISEASE FOR TURKEYConference Object21S145S145Q1WOS:000459985601184